Rezolute, Inc.
NASDAQ:RZLTBiotechnology
+$0.30 today
- Market cap
- $411.10M
- Beta
- 0.65
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.78
Volume 2.93M
Average 2.03M
RZLT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Rezolute, Inc.NASDAQ: RZLT
Research & Development · Q3 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q3 FY2026 research & development of $11.41M fell 25.3% year over year, behind the +0.0% change in trailing-twelve-month research & development. Sequentially, it fell 20.5% from the prior quarter. Over 3 fiscal years it compounded at +23.7% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -25.3% toward the trailing-twelve-month pace of +0.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 61.53M USD
- Year-over-year change
- +10.4%
- 4-year CAGR
- +42.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 61.53M | +10.4% |
| FY2024 | 2024-06-30 | 55.74M | +27.2% |
| FY2023 | 2023-06-30 | 43.81M | +34.9% |
| FY2022 | 2022-06-30 | 32.49M | +116.8% |
| FY2021 | 2021-06-30 | 14.99M | — |
Research & Development vs competitors
How RZLT compares with its peers on the latest reported figures
- RZLT's LTM Mar 2026 research & development of $59.77M is the 3rd highest of the 5 companies compared; the peer median is $59.33M.
- Its year-over-year change of +0.0% is the 3rd highest of 5, against a peer median of -23.4%.
- Over three fiscal years its annual growth of +23.7% compares with a peer median of -5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $770.95M | +12.5% | +2.0% | 115.2% | |
| LTM Mar 2026 | $104.71M | +22.1% | +23.1% | 28.3% | |
| LTM Mar 2026 | $59.77M | +0.0% | +23.7% | — | |
| LTM Mar 2026 | $13.94M | -59.3% | -21.6% | 1624.7% | |
| LTM Mar 2026 | $13.88M | -59.9% | -13.7% | 11.3% | |
| Peer median (excluding RZLT) | $59.33M | -23.4% | -5.8% | 71.8% | |
Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 13K | 0 | 0 | 0 | 0 |
| Gross Profit | (13K) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 14.99M | 32.49M | 43.81M | 55.74M | 61.53M |
| Selling, General & Admin | 7.91M | 9.36M | 12.18M | 14.68M | 18.37M |
| Operating Expenses | 22.88M | 41.84M | 55.99M | 70.42M | 79.89M |
| Depreciation & Amortization | 13K | 13K | 30K | 36K | 31K |
| EBITDA | (20.51M) | (39.24M) | (51.76M) | (68.42M) | (74.38M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (22.89M) | (41.84M) | (55.99M) | (70.42M) | (79.89M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 63K | 80K | 4.21M | 4.87M | 5.48M |
| Interest Expense | 375K | 1.81M | 0 | 0 | 0 |
| Other Income / Expenses | 1.99M | 783K | 4.2M | 1.96M | 5.48M |
| Income Before Tax | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.72) | (2.26) | (1.01) | (1.33) | (0.98) |
| EPS (Diluted) | (2.72) | (2.32) | (1.01) | (1.33) | (0.98) |
| Weighted Avg Shares | 7.67M | 18.2M | 51.19M | 51.47M | 76M |
| Weighted Avg Shares (Diluted) | 7.67M | 19.49M | 51.19M | 51.47M | 76M |
Rezolute, Inc.
NASDAQ:RZLT
Intrinsic Alpha fair value
Locked
Current Price
$4.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.